A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.
Clinical trial NCT02398552 · UNKNOWN
Trial details
- NCT number
- NCT02398552
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-01
- Primary completion
- 2017-03-01
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.